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Pneumocystis jiroveci (previously known as Pneumocystis carinii f. sp. hominis) pneumonia 
(PjP) [1] is a well-known opportunistic infection affecting immunocompromised hosts, especially 
patients infected with HIV. However, with the rising number of patients receiving 
immunosuppressive therapy, PjP is being increasingly recognised in immunosuppressed hosts 
who are not infected with HIV [2]. For instance, one previous study found PjP in 3.4--43% of 
solid organ transplant recipients not infected with HIV, with an especially high incidence among 
patients on long-term steroid therapy [3]. Though the exact pathogenesis of PjP remains obscure, 
it has been suggested that immunorestitution disease (IRD) contributes to the manifestation of 
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PjP [4]. Reported here are seven cases of PjP manifesting as IRD in HIV-negative 
immunosuppressed hosts. 
Between July 1995 and June 2003, 35 patients were diagnosed with PjP at the Queen Mary and 
United Christian Hospitals in Hong Kong based on the presence of radiologically proven 
pulmonary infiltrations, the presence of Pneumocystis jiroveci in bronchoalveolar lavage fluid, 
and symptoms consistent with the clinical picture of PjP infection, such as fever, cough, and 
dyspnoea. Twenty-five of the patients were HIV positive; 19 of these patients were newly 
diagnosed and had not begun highly active antiretroviral therapy at the time of presentation. The 
remaining 10 patients were HIV-negative immunosuppressed subjects with renal diseases 
(glomerulonephritis in 2, renal transplantation in 1), haematological conditions (immune 
thrombocytopenic purpura in 2), autoimmune diseases (bullous pemphigoid in 1, pemphigus 
vulgaris in 1, juvenile rheumatoid arthritis in 1), and solid organ tumour (thymoma in 1). The 
case of one patient with Cushing’s disease was reported previously [4]. The immunosuppressive 
therapy administered to these patients consisted of an endogenous steroid in one, steroid therapy 
in three, and a combination of steroids and cytotoxic treatment in five. 
Altogether there were 22 male and 13 female patients, and their ages ranged from 7 to 75 years 
(mean±SD, 43.3±13.9 years). Thirty of them were ethnic Chinese, four were Thai and one was 
Filipino. The most common clinical presentations of PjP were dyspnoea (80%), fever (80%), 
non-productive cough (54.3%), and productive cough with clear sputum (31.4%). A minority of 
the patients presented with chest pain (8.6%), general malaise (8.6%), anorexia (8.6%), dizziness 
(5.7%), sore throat (5.7%), and diarrhoea (5.7%). Oxygen desaturation with SaO2 <90% while on 
ambient air occurred in three of the patients. Chest radiographs revealed bilateral lesions in 30 
patients, whereas five patients had unilateral involvement. An alveolar pattern of radiographic 
lesions was shown in 19 patients, whereas interstitial radiographic lesions were found in the 
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remaining 16 patients. Unilateral pleural effusion was noted in one patient upon admission. 
Pneumothorax was not observed in any of our patients on presentation. None of the 35 patients 
had received prior chemoprophylaxis for PjP. High-dose intravenous co-trimoxazole was given to 
30 patients, and intravenous pentamidine was initiated in the remaining five patients. 
We defined IRD as an acute symptomatic presentation of PjP temporally related to the recovery 
of the immune system (as evidenced by an increase in the absolute lymphocyte count), which 
resulted in immunopathological damage associated with reversal of immunosuppressive 
processes, such as a reduction in the corticosteroid dose or a reduction in HIV viral load by 
HAART. Seven of the 35 patients fulfilled the case definition of IRD, with an upsurge of 
absolute lymphocyte counts being noted from the reduction of immunosuppression (median, 
300/μl; range, 290--740/μl) to the onset of IRD (median, 1,500/μl; range, 600--5,620/μl). The 
demographic characteristics of patients with and without reversal of immunosuppression before 
the clinical manifestation of PjP are listed in Table 1. 
All seven patients who developed symptomatic PjP during reversal of immunosuppression tested 
negative for HIV. Five of them had received chronic steroid therapy for more than 3 months. 
They had a higher mean age (53.1 vs 40.9 years, P=0.04) and a shorter mean duration of 
symptoms preceding admission (2.0 vs 19.9 days, P<0.01). They tended to be more hypoxemic 
(pO2 7.8 vs 10.9 kPa on ambient air, P=0.06), and they had a significantly higher mean 
lymphocyte count (1,918 vs 641/μl, P<0.01). When compared with those patients without 
reduction of immunosuppression, a significantly higher proportion of patients with IRD required 
steroid therapy as adjunctive treatment (100% vs 60.7%, P=0.04), and patients with IRD suffered 
more frequent opportunistic infections (57.1% vs 17.9%, P=0.03). Interestingly, steroid therapy 
was initiated after a median delay of 1.5 days following high-dose intravenous co-trimoxazole for 
PjP in four of the patients without IRD. Compared with patients without IRD, a higher proportion 
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of IRD patients was admitted to the intensive care unit (100% vs 53.6%, P=0.02), received 
mechanical ventilation (85.7% vs 32.1%, P=0.01), had a longer mean duration of hospital stay 
(37.3 vs 18.4 days, P<0.01), and died (42.9% vs 10.7%, P=0.04). 
The clinical manifestation of PjP as a form of IRD is not a rare phenomenon. In our study, the 
seven patients with this condition represented 20% of all patients with microbiological evidence 
of Pneumocystis jiroveci infection and 70% of the HIV-negative immunosuppressed patients with 
PjP. As seen in these patients, PjP occurring in the context of IRD is acute and fulminant, often 
associated with nonspecific findings on initial chest radiographs, and often associated with a high 
absolute lymphocyte count resulting from the tapering of immunosuppressive therapy or reversal 
of immunosuppressed status. All of our patients with IRD required steroid therapy adjunctive to 
antimicrobial treatment, and more than 80% of them required ventilatory support for acute 
respiratory failure. Unfortunately, the diagnosis of PjP was usually delayed in these patients 
because of its atypical presentation in this clinical setting. Mortality was significantly higher 
among the patients with IRD. 
Acute respiratory failure following HAART initiated during the treatment of PjP has been clearly 
documented as an IRD in HIV-infected patients [5, 6]. In three patients treated with HAART 
early after the diagnosis of PjP (i.e., 1--16 days), acute respiratory distress occurred shortly after 
HAART introduction (i.e., 7--17 days) [5], when the CD4+ lymphocyte count increased along 
with a concomitant reduction in viral load. Similar experience has been reported in another three 
patients [6]. All of these patients had severe respiratory distress as evidenced by PaO2 of less than 
70 mmHg, and they required the administration of steroids as anti-inflammatory therapy. Either 
HAART was given too early during the course of PjP disease (1--16 days), or the steroid was 
stopped too early (<15 days). The phenomenon of IRD in HIV-positive patients with PjP 
infection has been further substantiated by examination of the lungs and transbronchial biopsy 
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specimens, with histopathologic examination revealing mixed inflammatory infiltrates including 
macrophages, neutrophils, lymphocytes, and plasma cells. Almost all infiltrating lymphocytes 
were in T-cell lineage as assessed by immunophenotyping, and CD4+ and CD8+ lymphocyte 
subsets were equally represented in the tissue level [5]. 
In fact, rapid reduction of immunosuppressive therapy, such as steroid treatment, has been 
implicated as a predisposing factor for the development of PjP in HIV-negative patients [2, 7--9]. 
However, these cases were not all analyzed from a perspective of IRD. Serial changes of absolute 
lymphocyte counts were not noted or reported [2, 7--9]. It has been suggested that an upsurge of 
the absolute lymphocyte count, especially CD4+ lymphocyte counts in HIV-positive patients, can 
act as a surrogate marker for immunopathological damage during IRD in both HIV-negative and 
HIV-positive patients [4]. In each of our seven HIV-negative immunosuppressed patients, a 
consistent rise in the absolute lymphocyte count was observed from the time reduction of 
immunosuppression occurred to the onset of IRD. A similar trend of increasing CD4+ 
lymphocyte counts was also found in other HIV-positive cases before and during IRD [5, 6]. An 
upsurge in absolute lymphocyte counts at the time of IRD has been previously reported in 
patients with viral infections, such as polyomavirus and influenza A virus [10] as well as 
paradoxical deterioration of tuberculosis during anti-tuberculous therapy [11]. However, it must 
be emphasized that the number of circulating lymphocytes detected may not always represent the 
number in the affected tissues or their in vivo functional activity. For instance, in a case of PjP 
associated with steroid withdrawal that we reported previously, the lymphocyte count surged to a 
very high level, then rapidly decreased to a low level within 1 day. This was likely due to 
extremely severe immunorestitution, in which all of the lymphocytes migrated into the site of 
restitution to produce severe damage [4]. 
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With a better understanding of the IRD phenomenon in cases of Pneumocystis jiroveci infection, 
we may be able to prevent the occurrence of IRD in HIV-positive patients by delaying the 
initiation of HAART. However, it is even more important to recognise the atypical manifestation 
of IRD in HIV-negative immunosuppressed patients because the consequences are worse. Very 
often, a diagnosis cannot be achieved based on clinical and/or radiological features alone. 
Analysis of absolute lymphocyte counts taken serially from the time of reduction of 
immunosuppression to the time of presentation can alert clinicians to the possibility of IRD 
associated with occult pathogens such as Pneumocystis jiroveci, if an upsurge of lymphocyte 
counts is detected. 
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Table 1 Comparison of demographic characteristics of patients with or without immunosuppression reversal (IR) 
before the clinical manifestation of Pneumocystis jiroveci pneumonia (PjP) 
Characteristic With IR (n=7) Without IR 
(n=28) 
P value 
Mean age in years (SD) 53.1 (13.6) 40.9 (13.1) 0.04 
Male:female ratio 4:3 18:10 0.73 
Proven HIV infection 0 25 (89.3%) <0.01 
Presence of immunosuppressive conditions other than HIV 7 (100%)a 4 (14.3%) b <0.01 
Presence of other co-morbidities 1 (14.3%) c 7 (25%)d 0.55 
Chronic steroid therapy for more than 3 months 5 (71.4%) 1 (3.6%) <0.01 
Mean duration of symptoms to admission in days (SD) 2.0 (2.9) 19.9 (15.5) <0.01 
Classic interstitial infiltrates on initial chest radiograph 2 (28.6%) 14 (50%) 0.31 
Mean PaO2 (kPa) in ambient air (SD) 7.8 (1.3) 10.9 (3.6) 0.06 
Mean lymphocyte count in μl at presentation (SD) 1918 (1753) 641 (362) <0.01 
Clinical suspicion of PjP on admission 0 10 (35.7%) 0.03 
Mean days of anti-PjP therapy after onset of symptoms 
(SD) 
8.1 (4.3) 24.5 (17.0) 0.02 
Steroids as adjunctive anti-PjP therapy at acute phase 7 (100%) 17 (60.7%) 0.04 
Delayed use of steroids after initiation of anti-PjP therapy 0 4 (14.3%) 0.29 
Coinfection by other opportunistic pathogen(s) 4 (57.1%) e 5 (17.9%) f 0.03 
Mean length of stay in days (SD) 37.3 (28.2) 18.4 (10.3) <0.01 
Intensive care admission 7 (100%) 15 (53.6%) 0.02 
Mechanical ventilation 6 (85.7%) 9 (32.1%) 0.01 
Overall mortality 3 (42.9%) 3 (10.7%) 0.04 
aImmune thrombocytopenic purpura (2), glomerulonephritis (2), bullous pemphigoid (1), endogenous Cushing’s 
disease (1), renal transplantation (1) 
bPemphigus vulgaris (1), juvenile rheumatoid arthritis (1), thymoma (1), diffuse large cell lymphoma (1) 
cChronic hepatitis C (1) 
dOld tuberculosis (3), chronic hepatitis B (3), pregnancy at 12 weeks of gestation (1) 
eCMV antigenaemia (3), CMV hepatitis (1) 
fVaricella zoster virus reactivation (1), cytomegalovius (CMV) pneumonitis (1), cryptococcal meningitis (1), CMV 
antigenaemia & cryptococcal meningitis (1), and CMV retinitis & disseminated Penicillium marneffei (1).CXR, 
chest radiograph; HAART, highly active antiretroviral therapy 
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